


# Emerging Pathogens Solidarity System



A global system for sharing  
biological materials with epidemic or  
pandemic potential

# WHO Emerging Pathogens Solidarity System: Overall concept




# Two streams of work

## Stream 1

### Operationalization of the BioHub

- PHASE 1
  - Time limited: december 2021
  - For SARS CoV-2
  - Laboratory Spiez BSL4
  - Agreement with Swiss authorities (Memorandum of Understanding)
  - SMTAs testing
- PHASE 2
  - Expansion to other laboratories
  - Definition of criteria for sharing




## Stream 2

### Development of the global system

- Engaging with MS, commercial entities, partners, philanthropies, academia and CSO
- Definition of principles
- Definition of package of benefits
- Global goods (medical countermeasures)

# WHO EPSS: Sharing




## Focus

- Operationalization of sharing of dangerous biological substances
- Coalition of the willing - linkages with Nagoya protocol
- Limited to dangerous pathogens (priority of the R&D blueprint including disease X)

# WHO EPSS: A broad global system

## Focus


- The BioHub: a neutral, reliable, safe and secure repository (ies) for biological materials with epidemic or pandemic potential
- Development of system to allow for sustainable sharing
- Including Access and Benefit Sharing
- Aiming at faster development of global goods to make the world safer



# WHO EPSS: Allocation

## Focus

- Operationalization of sharing of dangerous biological substances
- Defining the various recipients/users
- Defining their interaction with the system, in particular their contribution



# A phased approach

UNTIL END DECEMBER 2021

- **Stream 1:**  
**Operationalization of the BioHub**
  - SARS-CoV2 (variants)
  - From one laboratory to a network of laboratories to add the discovery function
- **Stream 2:**  
**Discussion with MS** and other stakeholders to define system (March to December)

AFTER DECEMBER 2021

- **Stream 1:**
  - **Initial network of laboratory** defined with ToRs, SMTA and letter of agreements
  - Sustainable structure and funding
- **Stream 2:**
  - **Package of benefit defined**
  - Formalization of the system
    - Agreement with MS
    - Agreement with other stakeholders, industry, CSO

# Two scenarios

---

## SCENARIO 1

- **Sharing of known pathogen**
- Role of the BioHub
  - Further characterisation,
  - storage,
  - sequencing and
  - sharing with other laboratories

---

## SCENARIO 2

- **Sharing of unknown pathogen** at the start of an epidemic event
- Discovery of new pathogens requires sophisticated methods and high level security in the laboratory



# Understanding potential public health benefits

## Information and Risk Assessment

- Public health information and tools, (including regular reports, risk assessments and related tools, guidelines and lab protocols)
- Rapid access to GSD through relevant publicly accessible databases

## Development of Global Public Health Goods

- Development of countermeasures (vaccine, therapeutics, diagnostics and so on)
- Timely updated and evidence-based recommendations on countermeasures

## Capacity Building

- Eg: Training, mentoring and capacity strengthening

## Research

- Fostering international scientific projects with enhanced participation of scientists, from developing countries included proper acknowledgement in presentations and publications

Thank you